Discovery targets dormant bowel cancer cells before they form secondary tumours

Discovery targets dormant bowel cancer cells before they form secondary tumours

An international research team, led by the University of Melbourne, have discovered a way to control the stem cell behaviour responsible for the spread of bowel cancer.

The discovery will lead to treatments that target dormant cells, a major shift from conventional therapies that hit the growing only.

A cell surface receptor – called Frizzled 7 - is the key to the stem cell activity that results spreading. The majority of patients die from secondary cancers that spread throughout the body, not the primary cancer.

The findings have been published in Stem Cell Reports and herald an optimistic end to Bowel Cancer Awareness Month in June.

Lead researcher, Professor Elizabeth Vincan is the Head of the Cancer Biology Laboratory at the University of Melbourne and the Victorian Infectious Diseases Reference Laboratory at the Doherty Institute.

She says patients with bowel cancer often seek treatment once the cancer is advanced and has already spread to other parts of the body, most commonly the liver, where it can sit dormant for years before starting new cancer growth.

Her team has identified a molecule that is present in both actively growing and . The aim is to target the primary tumour in the bowel as well as the dormant cancer cells in secondary organs.

Bowel cancer is the second most common cancer in Australia and globally there were 1.4 million new cases and 694,000 deaths from bowel cancer in 2012 alone.

Conventional therapies and treatments have poor outcomes for bowel cancer patients because by the time they are detected, the cancer cells have spread to secondary organs, sitting dormant and undetected, until something triggers them to form a cancer again, and that then becomes the cause of death.

Previous research has shown a stem cell in the gut that is identified by a marker called Lgr5 plays a key role in initiating cancer growth.

This cell needs 'Wnt' proteins to regenerate the gut lining or epithelium (those tissues that line the surfaces of the gut) after it is damaged. And these Wnt proteins control cell function by binding to a known as 'Frizzled'. There are 10 of these Frizzled receptors but the one involved in the Lgr5 was not known.

"It was like searching for a piece of the puzzle," Professor Vincan said. "We found that Frizzled7 was the one we were looking for. That is the one that is important in Lgr5+ stem cells and that is the one to target in cancer.

"If you knock out Frizzled7 while the cells are in a dormant state they aren't able to make the tumour grow. The aim now is to try to get to those cells while they are dormant, before they start growing. It represents a shift in the targeted management of cancers.

"The next step is how to target Frizzled7 and develop anti-Frizzled7 antibody treatments that can be used in combination with other current therapies. We are collaborating with international scientists who are trialling imminent antibody treatments."


Explore further

Research finds target to prevent breast cancer relapse

More information: "Frizzled7 Functions as a Wnt Receptor in Intestinal Epithelial Lgr5+" Stem Cells DOI: dx.doi.org/10.1016/j.stemcr.2015.03.003
Journal information: Stem Cells , Stem Cell Reports

Citation: Discovery targets dormant bowel cancer cells before they form secondary tumours (2015, June 25) retrieved 11 December 2019 from https://medicalxpress.com/news/2015-06-discovery-dormant-bowel-cancer-cells.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
12 shares

Feedback to editors

User comments